



on December 4, 2003 (Date of Deposit).

Name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 01-1736-D)

Hom et al.

Before the Examiner:

T. Criares

Serial No.: 09/816,876

Art Unit: 1617

Filed: March 23, 2001

For: Compounds to Treat

## Alzheimer's Disease

## RESPONSE TO THE RESTRICTION REQUIREMENT


MAILED SEPTEMBER 4, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed September 4, 2003, Applicants elect the claims of Group V, i.e., claims 49-59, for prosecution. Further, Applicants elect the species of Example 53 on page 174. The compound of that example is named in the specification as 4-(*anti*)-([6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxyl-

2-(*R*)-isobutyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid: and can be represented by the following structure:




Applicants urge the Examiner to contact the Applicants' undersigned representative at (312) 913-0001 if it is believed that a discussion would expedite prosecution of this application.

Respectfully submitted,

Dated: December 4, 2003

By:

  
Steven J. Sarussi  
Reg. No. 32,784

McDonnell Boehnen  
Hulbert & Berghoff  
300 South Wacker Drive  
Chicago, Illinois 60606  
(312) 913-0001